About the Study

Pneumococcal disease is a leading cause of morbidity and mortality worldwide. Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing. Pneumonia can range in seriousness from mild to life-threatening.

Rochester Clinical Research is now seeking volunteers between the ages of 50 and 64 years old for a research study to evaluate the safety and efficacy of an investigational Pneumococcal vaccine.

This study is comparing 3 different doses of an investigational pneumococcal vaccine to the currently recommended Prevnar-20 vaccine. This study hopes to find a new pneumococcal vaccine that will potentially protect against strains not covered by the currently available vaccines.

There is NO chance of placebo in this study. All participants will receive a dose of the investigational vaccine or currently approved Prevnar-20.

This study will last approximately 6 months with 4 visits to our office and 5 telephone calls.

Study-related care is available to participants at no cost and health insurance is not required nor needed. Compensation of up to $937.50 is available for time and travel to those who qualify.

To qualify for this study you must be between the ages of 50 and 64 years old with no history of Pneumococcal vaccination OR history of Pneumococcal disease.


  • Be between the ages of 50 and 64 years old
  • No previous diagnosis of Pneumococcal disease
  • No history of receiving Pneumococcal vaccine